Alterola Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2019
April 02, 2021 at 11:12 pm IST
Share
Alterola Biotech, Inc. announced earnings results for the first quarter ended December 31, 2019. For the first quarter, the company announced operating loss was USD 104,693 compared to USD 52,387 a year ago. Net loss was USD 25,693 compared to USD 52,636 a year ago.
Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.